Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial
The DOI matches its Crossref record.
Abstract
Objective: Originally introduced into pharmacotherapy as an antiviral compound, amantadine was shown to also have multiple pharmacological effects on the central nervous system. In addition, only a few studies reported on certain antidepressive properties of amantadine. This effect was highlighted by the discovery of its antiviral effect on Borna disease virus (BDV), which is hypothesized to be an etiopathogenetic factor to subtypes of affective disorders. Therefore, the therapeutical use of amantadine in BDV‐infected depressive patients was investigated. Methods: In this open trial, amantadine was added to antidepressive and/or mood‐stabilizing compounds treating BDV‐infected depressed patients (n=25) with bipolar or major depressive disorders. Amantadine was given twice a day (100–300 mg/day) for a mean of 11 weeks. Antidepressive treatment response was measured on the Hamilton rating scale for depression (HAM‐D) and/or with an operationalized diagnostic criteria system (OPCRIT; version 3.31). Virological response was measured by expression of BDV infection parameters in blood samples. Results: The overall response rate of the amantadine augmentation in the BDV‐infected patients with regard to depressive symptoms was 68% after a mean of 2.9 weeks of treatment. Bipolar I patients improved faster and did not show any following hypomania. In addition, the decrease of depression tended to correspond with the decrease in viral activity. Conclusion: Amantadine appears to show a remarkable antidepressive efficacy in BDV‐infected depressive patients. The antidepressive effect in this open trial appeared to be comparable to standard antidepressives, possibly being a result of its antiviral effect against BDV as a potentially relevant etiopathogenetic factor in these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
The role of zinc in neurodegenerative inflammatory pathways in depression
Szewczyk, B., Kubera, M., & Nowak, G. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.02.010 · Cited by 176
Lee, E. E., Della Selva, M. P., Liu, A., & Himelhoch, S. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.003 · Cited by 124
Metadata
- Authors
- Dietrich, D. E., Bode, L., Spannhuth, C. W., Lau, T., Huber, T. J., Brodhun, B., Ludwig, H., & Emrich, H. M.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2000-03
- Volume
- 2
- Issue
- 1
- Pages
- 65-70
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W2078029525
- Cited by
- 58
- References
- 0
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. https://app.cochat.ai/papers/10.1034/j.1399-5618.2000.020110.x
- The paper
- Dietrich, D. E., Bode, L., Spannhuth, C. W., Lau, T., Huber, T. J., Brodhun, B., Ludwig, H., & Emrich, H. M. (2000). Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disorders. https://doi.org/10.1034/j.1399-5618.2000.020110.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.